MINNEAPOLIS , Jan. 27, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) is set to be a first mover in the artificial intelligence (AI) powered drug discovery market that POAI expects will grow to $20 billion in the next three years, reported the Company today in outlining its
MINNEAPOLIS , Jan. 13, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) reported the preliminary results of its Discovery 2021 program today, announcing that its Helomics subsidiary’s evaluation demonstrated their proprietary Artificial Intelligence (AI) program CoRE™ (Computational
MINNEAPOLIS , Dec. 27, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI) , a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced today that the Company’s Annual Meeting of Stockholders was convened at 3:00 p.m.
EAGAN, Minn. , Dec. 21, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology , (POAI), a knowledge-driven company focused on applying artificial intelligence (AI) to develop personalized cancer therapies, is moving in the right direction. In November 2021 , POAI acquired zPREDICTA, a cutting edge cancer
Bush to lead Predictive Oncology’s novel sales effort towards cancer research technologies EAGAN, Minn. , Dec. 07, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology , (POAI), a knowledge-driven company focused on applying artificial intelligence (AI) to develop personalized cancer therapies, today
zPREDICTA has developed a patented tumor-specific 3D cell culture platform that is complementary to Predictive Oncology’s Artificial Intelligence (AI) platform developed by Helomics. zPREDICTA’s uniquely designed 3D culture systems create a tumor microenvironment that is closer to the patient’s
EAGAN, Minn. , Nov. 10, 2021 (GLOBE NEWSWIRE) -- Results from the third quarter show strong potential for future growth, said Predictive Oncology (Nasdaq: POAI) today, announcing financial results for the quarter ended September 30, 2021 . All three of Predictive Oncology’s reportable segments
Predictive Oncology is leveraging AI to streamline drug discovery and development, improve outcomes in clinical testing and forge a new frontier of cancer research MINNEAPOLIS , Oct. 19, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology , an oncology and cancer research company using big data and
MINNEAPOLIS , Sept. 15, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI) , a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, is excited to announce that Raymond F. Vennare was elected to the Board of Directors,
MINNEAPOLIS , Aug. 18, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI) , a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced today that on August 17, 2021 , the stockholders approved an amendment to the